NASDAQ:XBITXBiotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding XBiotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.51 +0.54 (+3.87 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$14.03Now: $14.51▼$14.6050-Day Range$13.30MA: $14.19▼$14.8852-Week Range$6.84Now: $14.51▼$26.40Volume89,547 shsAverage Volume152,570 shsMarket Capitalization$418.61 millionP/E Ratio1.00Dividend YieldN/ABeta1.42 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingXBiotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, XBiotech has a potential upside of 58.5% from its current price of $14.51.Amount of Analyst CoverageXBiotech has only been the subject of 1 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesXBiotech has received 311 “outperform” votes. (Add your “outperform” vote.)Underperform VotesXBiotech has received 184 “underperform” votes. (Add your “underperform” vote.)Community SentimentXBiotech has received 62.83% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote “Outperform” if you believe XBIT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldXBiotech does not currently pay a dividend.Dividend GrowthXBiotech does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, XBiotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 30.98% of the stock of XBiotech is held by insiders.Percentage Held by InstitutionsOnly 15.21% of the stock of XBiotech is held by institutions. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of XBiotech is 1.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.29.Price to Earnings Ratio vs. SectorThe P/E ratio of XBiotech is 1.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.71.Price to Book Value per Share RatioXBiotech has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XBIT Previous Symbol CUSIPN/A CIK1626878 Webwww.xbiotech.com Phone512-386-2900Debt Debt-to-Equity RatioN/A Current Ratio25.20 Quick Ratio25.20Price-To-Earnings Trailing P/E Ratio1.00 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$18.20 per share Price / Book0.80Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$668.63 million Net MarginsN/A Return on Equity-8.31% Return on Assets-7.82%Miscellaneous Employees56 Outstanding Shares28,850,000Market Cap$418.61 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:XBIT Rates by TradingView Receive XBIT News and Ratings via Email Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. XBiotech (NASDAQ:XBIT) Frequently Asked Questions How has XBiotech's stock been impacted by COVID-19 (Coronavirus)? XBiotech's stock was trading at $10.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XBIT stock has increased by 35.4% and is now trading at $14.51. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of XBiotech? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XBiotech. When is XBiotech's next earnings date? XBiotech is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for XBiotech. How were XBiotech's earnings last quarter? XBiotech Inc (NASDAQ:XBIT) released its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). View XBiotech's earnings history. What price target have analysts set for XBIT? 2 analysts have issued 12 month price targets for XBiotech's shares. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's stock price to reach $23.00 in the next year. This suggests a possible upside of 58.5% from the stock's current price. View analysts' price targets for XBiotech. Has XBiotech been receiving favorable news coverage? News articles about XBIT stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XBiotech earned a news impact score of -2.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about XBiotech. Are investors shorting XBiotech? XBiotech saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,980,000 shares, a decline of 6.6% from the June 15th total of 2,120,000 shares. Based on an average trading volume of 228,300 shares, the short-interest ratio is currently 8.7 days. Approximately 14.2% of the shares of the company are sold short. View XBiotech's Current Options Chain. Who are some of XBiotech's key competitors? Some companies that are related to XBiotech include I-Mab (IMAB), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), Intra-Cellular Therapies (ITCI), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT), BELLUS Health (BLUSF), Mersana Therapeutics (MRSN), Cytokinetics (CYTK), MacroGenics (MGNX), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC) and Akcea Therapeutics (AKCA). View all competitors. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Cidara Therapeutics (CDTX), Micron Technology (MU), Novavax (NVAX), Ocular Therapeutix (OCUL), Sanofi (SNY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). Who are XBiotech's key executives? XBiotech's management team includes the following people: Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board When did XBiotech IPO? (XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO. What is XBiotech's stock symbol? XBiotech trades on the NASDAQ under the ticker symbol "XBIT." How do I buy shares of XBiotech? Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is XBiotech's stock price today? One share of XBIT stock can currently be purchased for approximately $14.51. How big of a company is XBiotech? XBiotech has a market capitalization of $418.61 million. The biopharmaceutical company earns $668.63 million in net income (profit) each year or ($0.68) on an earnings per share basis. XBiotech employs 56 workers across the globe. What is XBiotech's official website? The official website for XBiotech is www.xbiotech.com. How can I contact XBiotech? XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
